Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Nat Med

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    November 2022

  1. Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic.
    Nat Med. 2022 Nov 4. pii: 10.1038/s41591-022-02065.

    Intranasal COVID-19 vaccine fails to induce mucosal immunity.
    Nat Med. 2022 Nov 3. pii: 10.1038/d41591-022-00106.

    October 2022
  3. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02064.
    PubMed     Abstract available

  4. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    PubMed     Abstract available

  5. SCHEAFFER SM, Lee D, Whitener B, Ying B, et al
    Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Nat Med. 2022 Oct 20. pii: 10.1038/s41591-022-02092.
    PubMed     Abstract available

  6. ZAECK LM, Lamers MM, Verstrepen BE, Bestebroer TM, et al
    Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Nat Med. 2022 Oct 18. pii: 10.1038/s41591-022-02090.
    PubMed     Abstract available

  7. MENTZER AJ, O'Connor D, Bibi S, Chelysheva I, et al
    Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02078.
    PubMed     Abstract available

    Boosting with updated COVID-19 mRNA vaccines.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02048.

  9. CHALKIAS S, Eder F, Essink B, Khetan S, et al
    Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02031.
    PubMed     Abstract available

    September 2022
    mRNA vaccines boost BioNTech's CAR T cell therapy.
    Nat Med. 2022 Sep 1. pii: 10.1038/d41591-022-00091.

    August 2022
  11. PALMER CD, Rappaport AR, Davis MJ, Hart MG, et al
    Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2022;28:1619-1629.
    PubMed     Abstract available

    July 2022
  12. LUONG NGUYEN LB, Ghosn J, Durier C, Tachot C, et al
    A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.
    Nat Med. 2022 Jul 13. pii: 10.1038/d41591-022-00077.

  13. JARA A, Undurraga EA, Zubizarreta JR, Gonzalez C, et al
    Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.
    Nat Med. 2022;28:1377-1380.
    PubMed     Abstract available

    June 2022
  14. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.

  15. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    PubMed     Abstract available

    May 2022
  16. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.

  17. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.

  18. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    PubMed     Abstract available

  19. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    PubMed     Abstract available

    April 2022
  20. O'LEARY K
    Single vaccine shot protects against cervical cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00056.

  21. ARBEL R, Sergienko R, Friger M, Peretz A, et al
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Nat Med. 2022 Apr 25. pii: 10.1038/s41591-022-01832.
    PubMed     Abstract available

  22. PUHACH O, Adea K, Hulo N, Sattonnet P, et al
    Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Nat Med. 2022 Apr 8. pii: 10.1038/s41591-022-01816.
    PubMed     Abstract available

  23. PAJON R, Paila YD, Girard B, Dixon G, et al
    Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
    Nat Med. 2022;28:823-830.
    PubMed     Abstract available

    March 2022
    Russian COVID-19 vaccine in jeopardy after Ukraine invasion.
    Nat Med. 2022 Mar 15. pii: 10.1038/d41591-022-00042.

  25. PERTWEE E, Simas C, Larson HJ
    An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
    Nat Med. 2022 Mar 10. pii: 10.1038/s41591-022-01728.
    PubMed     Abstract available

  26. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.

  27. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Nat Med. 2022;28:477-480.
    PubMed     Abstract available

  28. GAO Y, Cai C, Grifoni A, Muller TR, et al
    Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
    Nat Med. 2022;28:472-476.
    PubMed     Abstract available

    February 2022
  29. DU Z, Wang L, Pandey A, Lim WW, et al
    Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Nat Med. 2022 Feb 24. pii: 10.1038/s41591-022-01736.
    PubMed     Abstract available

  30. AULADELL M, Phuong HVM, Mai LTQ, Tseng YY, et al
    Influenza virus infection history shapes antibody responses to influenza vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-022-01690.
    PubMed     Abstract available

    Exploring the landscape of immune responses to influenza infection and vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-021-01656.

  32. WEI J, Pouwels KB, Stoesser N, Matthews PC, et al
    Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Nat Med. 2022 Feb 14. pii: 10.1038/s41591-022-01721.
    PubMed     Abstract available

  33. CERQUEIRA-SILVA T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, et al
    Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Nat Med. 2022 Feb 9. pii: 10.1038/s41591-022-01701.
    PubMed     Abstract available

  34. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Feb 4. pii: 10.1038/s41591-022-01730.

  35. ANDREWS SF, Raab JE, Gorman J, Gillespie RA, et al
    A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01636.
    PubMed     Abstract available

  36. HOUSER KV, Chen GL, Carter C, Crank MC, et al
    Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01660.
    PubMed     Abstract available

    January 2022
  37. WRATIL PR, Stern M, Priller A, Willmann A, et al
    Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Nat Med. 2022 Jan 28. pii: 10.1038/s41591-022-01715.
    PubMed     Abstract available

  38. LI J, Hou L, Guo X, Jin P, et al
    Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Nat Med. 2022 Jan 27. pii: 10.1038/s41591-021-01677.
    PubMed     Abstract available

  39. PEREZ-THEN E, Lucas C, Monteiro VS, Miric M, et al
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01705.
    PubMed     Abstract available

  40. CHENG SMS, Mok CKP, Leung YWY, Ng SS, et al
    Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01704.
    PubMed     Abstract available

  41. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England.
    Nat Med. 2022 Jan 14. pii: 10.1038/s41591-022-01699.
    PubMed     Abstract available

  42. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01666.
    PubMed     Abstract available

  43. WARD JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, et al
    The French health pass holds lessons for mandatory COVID-19 vaccination.
    Nat Med. 2022 Jan 12. pii: 10.1038/s41591-021-01661.

    COVID-19 has revealed a pandemic of inequality.
    Nat Med. 2022;28:17.

    December 2021
  45. PATONE M, Mei XW, Handunnetthi L, Dixon S, et al
    Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Nat Med. 2021 Dec 14. pii: 10.1038/s41591-021-01630.
    PubMed     Abstract available

    As COVID-19 vaccines arrive in Africa, Omicron is reducing supply and increasing demand.
    Nat Med. 2021 Dec 13. pii: 10.1038/d41591-021-00073.

  47. Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.

  48. O'LEARY K
    A malaria vaccine at last.
    Nat Med. 2021;27:2057.

  49. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.

  50. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    PubMed     Abstract available

  51. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    PubMed     Abstract available

    COVID-19 in 2022: controlling the pandemic is within our grasp.
    Nat Med. 2021;27:2070.

    COVID-19 timeline of events.
    Nat Med. 2021;27:2054-2055.

  54. MAY M
    Eight unanswered questions about the COVID-19 pandemic.
    Nat Med. 2021;27:2058-2061.

  55. ARNOLD C
    11 clinical trials that will shape medicine in 2022.
    Nat Med. 2021;27:2062-2064.

    November 2021
  56. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Nov 29. pii: 10.1038/s41591-021-01644.

  57. O'LEARY K
    An mRNA vaccine against tick bites.
    Nat Med. 2021 Nov 25. pii: 10.1038/d41591-021-00071.

  58. JUNO JA, Wheatley AK
    Boosting immunity to COVID-19 vaccines.
    Nat Med. 2021 Nov 11. pii: 10.1038/s41591-021-01560.

  59. O'LEARY K
    HPV vaccines beat cervical cancer.
    Nat Med. 2021 Nov 11. pii: 10.1038/d41591-021-00068.

  60. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    PubMed     Abstract available

  61. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
    Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
    PubMed     Abstract available

  62. FENG S, Phillips DJ, White T, Sayal H, et al
    Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:2032-2040.
    PubMed     Abstract available

    October 2021
  63. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Oct 25. pii: 10.1038/s41591-021-01556.
    PubMed     Abstract available

  64. POUWELS KB, Pritchard E, Matthews PC, Stoesser N, et al
    Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
    Nat Med. 2021 Oct 14. pii: 10.1038/s41591-021-01548.
    PubMed     Abstract available

  65. ALI M, Khan J, Ahmad N, Khan H, et al
    COVID-19 vaccination gives hope to eradicate polio.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01518.

    September 2021
  66. O'LEARY K
    Low-dose mRNA vaccination measures up.
    Nat Med. 2021 Sep 30. pii: 10.1038/d41591-021-00060.

  67. SHROFF RT, Chalasani P, Wei R, Pennington D, et al
    Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
    Nat Med. 2021 Sep 30. pii: 10.1038/s41591-021-01542.
    PubMed     Abstract available

  68. CHOOKAJORN T, Kochakarn T, Wilasang C, Kotanan N, et al
    Southeast Asia is an emerging hotspot for COVID-19.
    Nat Med. 2021;27:1495-1496.

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.